ADA Guidelines

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Top

Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428. The authors of the current prospective study sought to examine the potential benefits of laparoscopic Roux-en-Y gastric bypass (LRYGB) among those with BMI 30-34.9 kg/m2 (class I obesity) and type 2 diabetes.

Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study

Top

Lorenzo C, Lee R, Haffner SM. Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study. Diabetes Care. 2012 Aug 24. Epub ahead of print. The Diabetes Prevention Program (DPP) reported no racial/ethnic differences in the incidence of diabetes in individuals with impaired glucose tolerance (IGT). Therefore, it has been hypothesized that factors associated with racial/ethnic disparities act prior to the development of IGT.

Nonnutritive Sweeteners: Current Use and Health Perspectives: A Scientific Statement from the American Heart Association and the American Diabetes Association

Top

Gardner C, Wylie-Rosett J, Gidding SS, Steffen LM, Johnson RK, Reader D, Lichtenstein AH. Nonnutritive Sweeteners: Current Use and Health Perspectives: A Scientific Statement from the American Heart Association and the American Diabetes Association. On behalf of the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, and the American Diabetes Association. Diabetes Care. 2012 Aug;35(8):1798-1808. Epub 2012 Jul 9.

ARIC Study: Examining Hypertension Risk Based on A1C

Top

Bower JK, Appel JL, Matsushita K, et al. ARIC Study: Examining Hypertension Risk Based on A1C. Diabetes Care. 2012;35:1031-1037. Bower and colleagues examined the role of A1C as a predictor of hypertension among subjects with and without diabetes in the Atherosclerosis Risk in Communities (ARIC) study.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

A clinical trial to maintain glycemic control in youth with type 2 diabetes

Top

TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. Epub ahead of print.The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study was a multicenter, randomized clinical trial that examined whether rosiglitazone plus metformin or intensive lifestyle intervention plus metformin initiated early in the disease course of youth-onset type 2 diabetes would maintain acceptable glycemic control better than metformin monotherapy.

Bariatric surgery versus intensive medical therapy in obese patients with diabetes

Top

Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567-1576. The Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) study, conducted by Schauer and colleagues, was a randomized, controlled trial comparing intensive medical therapy with surgical treatment to improve glycemic control in 150 obese subjects with type 2 diabetes.

Patients' education, and its impact on care outcomes, resource consumption and working conditions: Data from the IDMPS

Top

Gagliardino JJ, Aschner P, Baik SH, Chan J, Chantelot JM, Ilkova H, Ramachandran A; IDMPS investigators. Patients' education, and its impact on care outcomes, resource consumption and working conditions: Data from the International Diabetes Management Practices Study (IDMPS). Diabetes Metab. 2011 Oct 21. [Epub ahead of print]. To evaluate the impact of diabetes education provided to patients with type 2 diabetes mellitus (T2DM) in non-controlled studies ("real-world conditions") on quality of care, resource consumption and conditions of employment.

Efficacy & Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared w/ Exenatide Twice Daily & Sitagliptin in Type 2 Diabetes Mellitus

Top

Pinelli NR, Hurren KM. Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis (July/August). Ann Pharmacother. 2011 Jul 5. [Epub ahead of print]. Long-acting glucagon-like peptide-1 receptor agonists (LA-GLP-1RAs) may deliver additional therapeutic benefits over other available incretin-based therapies.

1 2 3 4 5 6 7 8 Next